While patent expansion supports long-term value, traders should remain cautious given the company's minimal cash reserves ($0.2M) and going concern uncertainty noted in the recent 20-F. Monitor upcoming Phase 3 trial initiation and financing activities.
Price Chart
Executive Summary
NeuroSense Therapeutics announced it has been granted a Brazilian patent for its PrimeC composition, extending patent protection through October 2042. This follows prior grants in the U.S. and Australia and strengthens the company's global intellectual property portfolio for its lead drug candidate.
Key Facts
- NeuroSense granted Brazilian patent No. BR 112024007727-6 for PrimeC composition
- Patent protection extends through October 2042
- Follows prior patent grants in the U.S. (patent 12,097,185) and Australia (2022370513)
- Strengthens global IP portfolio for PrimeC, which is in late-clinical development for ALS and Alzheimer's disease
Financial Impact
No immediate financial impact disclosed; strengthens long-term IP position for potential commercialization
Risk Factors
- Limited cash reserves raise substantial doubt about going concern
- Dependence on successful clinical trial outcomes and future financing
- Patent protection does not guarantee commercial success or regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-040185 |
| Document: ea0285169-6k_neuro.htm | 0001213900-26-040185 |
| Document: 0001213900-26-040185-index-headers.html | 0001213900-26-040185 |
| Document: 0001213900-26-040185-index.html | 0001213900-26-040185 |
| Document: 0001213900-26-040185.txt | 0001213900-26-040185 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 20w ago | 6-K | $0.1451 $0.0500 | ▼ −65.54% | ▼ −69.35% | — |
Jun 8, 2026 20w ago | 6-K | $0.1500 $0.0456 | ▼ −69.60% | ▼ −72.65% | — |
Apr 28, 2026 26w ago | 6-K | $0.2080 $0.0601 | ▼ −71.11% | ▼ −75.10% | — |
Apr 24, 2026 26w ago | 6-K | $0.2080 $0.0811 | ▼ −61.01% | ▼ −66.09% | — |
Apr 6, 2026 29w ago | 6-K | $0.2080 $0.0733 | ▼ −64.76% | ▼ −78.23% | — |
Apr 3, 2026 29w ago | 6-K | $0.2080 $0.0733 | ▲ +64.76% | ▲ +78.23% | — |
Apr 1, 2026 29w ago | 3 | $0.2080 $0.0630 | ▼ −69.71% | ▼ −83.87% | — |
Mar 31, 2026 30w ago | 20-F / 6-K | $0.2080 $0.2080 | · 0.00% | ▼ −13.20% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers